HRP20050899A2 - Novel phosphonic acid compounds as inhibitors of serine proteases - Google Patents

Novel phosphonic acid compounds as inhibitors of serine proteases

Info

Publication number
HRP20050899A2
HRP20050899A2 HR20050899A HRP20050899A HRP20050899A2 HR P20050899 A2 HRP20050899 A2 HR P20050899A2 HR 20050899 A HR20050899 A HR 20050899A HR P20050899 A HRP20050899 A HR P20050899A HR P20050899 A2 HRP20050899 A2 HR P20050899A2
Authority
HR
Croatia
Prior art keywords
inhibitors
acid compounds
phosphonic acid
serine proteases
novel phosphonic
Prior art date
Application number
HR20050899A
Other languages
English (en)
Croatian (hr)
Inventor
Michael
Harold
Powell Eugene
De Garavilla Lawrence
Original Assignee
Ortho-Mcneil Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical filed Critical Ortho-Mcneil Pharmaceutical
Publication of HRP20050899A2 publication Critical patent/HRP20050899A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HR20050899A 2003-04-16 2005-10-14 Novel phosphonic acid compounds as inhibitors of serine proteases HRP20050899A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/414,782 US7459461B2 (en) 2001-10-19 2003-04-16 Phosphonic acid compounds as inhibitors of serine proteases
PCT/US2004/011490 WO2004094441A2 (en) 2003-04-16 2004-04-14 Piperazine containing phosphonic acid compounds as inhibitors of serine proteases

Publications (1)

Publication Number Publication Date
HRP20050899A2 true HRP20050899A2 (en) 2006-09-30

Family

ID=33309497

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050899A HRP20050899A2 (en) 2003-04-16 2005-10-14 Novel phosphonic acid compounds as inhibitors of serine proteases

Country Status (21)

Country Link
US (17) US7459461B2 (zh)
EP (1) EP1620446B1 (zh)
JP (1) JP4526534B2 (zh)
KR (1) KR101106574B1 (zh)
CN (1) CN100475824C (zh)
AU (1) AU2004232941B2 (zh)
BR (1) BRPI0409566A (zh)
CA (1) CA2523203C (zh)
CR (1) CR8046A (zh)
EA (1) EA200501463A1 (zh)
EC (1) ECSP056106A (zh)
ES (1) ES2399884T3 (zh)
HR (1) HRP20050899A2 (zh)
ME (1) MEP48608A (zh)
MX (1) MXPA05011218A (zh)
NO (1) NO20055396L (zh)
NZ (1) NZ543139A (zh)
RS (1) RS20050778A (zh)
UA (1) UA80869C2 (zh)
WO (1) WO2004094441A2 (zh)
ZA (1) ZA200509249B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459461B2 (en) * 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
US20060293298A1 (en) * 2003-04-10 2006-12-28 Bamford Mark J Compounds
KR101326537B1 (ko) * 2006-11-30 2013-11-08 (주)아모레퍼시픽 카텝신 ｇ 발현 억제제 조성물
US8440637B2 (en) * 2007-10-04 2013-05-14 Santaris Pharma A/S Combination treatment for the treatment of hepatitis C virus infection
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
TWI501962B (zh) 2009-12-25 2015-10-01 Daiichi Sankyo Co Ltd 7-membered ring compounds and their pharmaceutical use
US10744179B2 (en) 2014-09-18 2020-08-18 The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy Method for treatment of inflammatory skin disorders with inhibitors of IL-36 proteolytic processing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633914A (zh) 1962-06-22
US4511551A (en) 1982-11-18 1985-04-16 Unique Technologies, Incorporated Method and composition for the detection of a precancerous or leukemic condition in mammals
AT380490B (de) * 1984-09-06 1986-05-26 Voest Alpine Ag Vorrichtung zur gewinnung der fuehlbaren waerme von schuettfaehigem heissgut
JPS61151199A (ja) * 1984-12-26 1986-07-09 Otsuka Pharmaceut Factory Inc カルボン酸アミド誘導体
US4704382A (en) * 1985-07-29 1987-11-03 G. D. Searle & Co. Phenylpiperazine phosphonates
US4822780A (en) * 1987-07-08 1989-04-18 Otsuka Pharmaceutical Factory, Inc. Carboxamide compounds
US5508273A (en) 1993-12-30 1996-04-16 Ortho Pharmaceutical Corporation Substituted phosphonic acids and derivatives useful in treating bone wasting diseases
DK0871454T3 (da) 1995-07-17 2004-03-22 Cephalon Inc Phosphorholdige inhibitorer af cystein- og serinprotease
EP0940400A4 (en) * 1996-10-25 2002-10-02 Mitsubishi Pharma Corp NOVEL HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USE FOR MEDICINAL PURPOSES
WO1999045928A1 (fr) * 1998-03-11 1999-09-16 Welfide Corporation INHIBITEURS DE PRODUCTION D'ANTICORPS IgE ET INHIBITEURS DE MALADIES AUTO-IMMUNES
US7459461B2 (en) 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases
AU2002356818C1 (en) 2001-10-19 2009-10-22 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases
WO2007047431A2 (en) * 2005-10-12 2007-04-26 Kalypsys, Inc. Sulfonyl-substituted aryl compounds as modulators of peroxisome proliferator activated receptors

Also Published As

Publication number Publication date
ES2399884T3 (es) 2013-04-04
US20090131371A1 (en) 2009-05-21
US20110092705A1 (en) 2011-04-21
AU2004232941B2 (en) 2011-07-28
ECSP056106A (es) 2006-03-01
EP1620446B1 (en) 2012-10-24
US8497373B2 (en) 2013-07-30
US20090143336A1 (en) 2009-06-04
US20120238528A1 (en) 2012-09-20
RS20050778A (sr) 2008-04-04
CR8046A (es) 2009-01-16
US20110092457A1 (en) 2011-04-21
CN1832950A (zh) 2006-09-13
US8461195B2 (en) 2013-06-11
US8304430B2 (en) 2012-11-06
CA2523203C (en) 2013-06-11
EA200501463A1 (ru) 2006-08-25
US20090118504A1 (en) 2009-05-07
EP1620446A2 (en) 2006-02-01
KR20060006929A (ko) 2006-01-20
WO2004094441A2 (en) 2004-11-04
US8247599B2 (en) 2012-08-21
NO20055396D0 (no) 2005-11-15
US7459461B2 (en) 2008-12-02
US20110319363A1 (en) 2011-12-29
US20130281407A1 (en) 2013-10-24
CN100475824C (zh) 2009-04-08
US20090124581A1 (en) 2009-05-14
US20090137528A1 (en) 2009-05-28
US20090131671A1 (en) 2009-05-21
WO2004094441A3 (en) 2005-10-13
JP2006523705A (ja) 2006-10-19
AU2004232941A1 (en) 2004-11-04
US8394804B2 (en) 2013-03-12
US20090118234A1 (en) 2009-05-07
US8178673B2 (en) 2012-05-15
CA2523203A1 (en) 2004-11-04
BRPI0409566A (pt) 2006-04-18
MXPA05011218A (es) 2006-07-06
US8198440B2 (en) 2012-06-12
ZA200509249B (en) 2007-01-31
US20040082544A1 (en) 2004-04-29
JP4526534B2 (ja) 2010-08-18
US20120283221A1 (en) 2012-11-08
US20110086819A1 (en) 2011-04-14
KR101106574B1 (ko) 2012-01-19
NO20055396L (no) 2006-01-04
US20090118508A1 (en) 2009-05-07
UA80869C2 (en) 2007-11-12
US8212039B2 (en) 2012-07-03
MEP48608A (en) 2011-02-10
US8703957B2 (en) 2014-04-22
US20090118235A1 (en) 2009-05-07
NZ543139A (en) 2009-02-28
US8609888B2 (en) 2013-12-17
US8207338B2 (en) 2012-06-26

Similar Documents

Publication Publication Date Title
HRP20050899A2 (en) Novel phosphonic acid compounds as inhibitors of serine proteases
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
EA200601358A1 (ru) Новые ингибиторы химазы
HRP20070043A2 (en) Antiviral compounds
TN2014000079A1 (en) Selective and reversible inhibitors of ubiquitin specific protease 7
EA201070247A1 (ru) Ингибиторы протеасом
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
EA200601141A1 (ru) Сульфонамидные производные для лечения заболеваний
CR9331A (es) Inhibidores de vegf-r2 y metodos
DE602006020875D1 (de) Oberflächenaktive peroxycarbonsäurezusammensetzungen
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
UY33832A (es) Inhibidores de la faah.
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
EA200802054A1 (ru) Ингибиторы фермента
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
EA200501399A1 (ru) Производные бензопирана, которые могут использоваться при лечении воспалительных заболеваний
CY1105166T1 (el) Ενωσεις φωσφονικου οξεος σαν αναστολεις πρωτεασων σepινης
EA201170209A1 (ru) Производные пиперазина, применяемые в качестве модуляторов кальциевого канала ca2.2
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
ECSP077240A (es) Variantes mejoradas de la aprotinina
EA201001823A1 (ru) Новые гетероциклические карбоксамиды для применения в качестве ингибиторов тромбина
DK1819704T3 (da) Pyrrolopyridin-2-carboxylsyre-amid-derivat anvendelig som inhibitor af glycogenphosphorylase
EA200702584A1 (ru) Спиробензимидазолы как ингибиторы секреции соляной кислоты
EA200900510A1 (ru) Дифторосодержащие соединения в качестве ингибиторов цистеиновых протеаз

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20120307

Year of fee payment: 9

OBST Application withdrawn